Keith A Josephs

List of Publications by Year
in descending order

334 papers	31,998 citations	6592 79 h-index	5101 166 g-index
338 all docs	338 docs citations	338 times ranked	19108 citing authors

#	Article	IF	Citations
1	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	3.8	4,176
2	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
3	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.5	1,445
4	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
5	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	3.7	624
6	Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology, 2006, 66, 41-48.	1.5	435
7	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
8	Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathologica, 2011, 122, 137-153.	3.9	375
9	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
10	REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology, 2010, 75, 494-499.	1.5	347
11	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
12	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain, 2012, 135, 1522-1536.	3.7	325
13	Neuropathology of variants of progressive supranuclear palsy. Current Opinion in Neurology, 2010, 23, 394-400.	1.8	312
14	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
15	Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau). Journal of Molecular Neuroscience, 2011, 45, 384-389.	1.1	295
16	Staging TDP-43 pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 441-450.	3.9	278
17	When DLB, PD, and PSP masquerade as MSA. Neurology, 2015, 85, 404-412.	1.5	272
18	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	1.4	271

#	Article	IF	Citations
19	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	3.9	244
20	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurology, The, 2013, 12, 978-988.	4.9	232
21	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
22	Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging, 2008, 29, 280-289.	1.5	221
23	Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology, 2008, 70, 1850-1857.	1.5	220
24	Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions. Alzheimer Disease and Associated Disorders, 2007, 21, S14-S18.	0.6	219
25	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
26	Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology, 2005, 64, 2033-2039.	1.5	214
27	The apraxia of speech rating scale: A tool for diagnosis and description of apraxia of speech. Journal of Communication Disorders, 2014, 51, 43-50.	0.8	189
28	Î²â€amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 2008, 63, 204-212.	2.8	187
29	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 142-151.	0.9	184
30	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
31	Neurofilament inclusion body disease: a new proteinopathy?. Brain, 2003, 126, 2291-2303.	3.7	176
32	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
33	Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase, 2005, 11, 283-296.	0.2	173
34	Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Current Opinion in Neurology, 2008, 21, 688-692.	1.8	173
35	IgLON5 antibody. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e385.	3.1	172
36	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170

#	Article	IF	Citations
37	Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica, 2013, 126, 537-544.	3.9	168
38	Frontotemporal dementia and related disorders: Deciphering the enigma. Annals of Neurology, 2008, 64, 4-14.	2.8	165
39	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
40	Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank. Movement Disorders, 2003, 18, 1018-1026.	2.2	155
41	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
42	Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology, 2009, 73, 1443-1450.	1.5	153
43	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
44	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. Parkinsonism and Related Disorders, 2011, 17, 599-605.	1.1	146
45	Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathology and Applied Neurobiology, 2004, 30, 369-373.	1.8	145
46	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology, 2008, 70, 25-34.	1.5	143
47	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. Neurology, 2013, 81, 337-345.	1.5	142
48	[¹⁸F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	2.2	136
49	The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795.	3.7	134
50	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	3.9	133
51	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	1.1	133
52	Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration. Journal of Neuropathology and Experimental Neurology, 2006, 65, 396-405.	0.9	129
53	Benign Tremulous Parkinsonism. Archives of Neurology, 2006, 63, 354.	4.9	129
54	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125

#	Article	IF	Citations
55	Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathologica, 2008, 116, 215-220.	3.9	124
56	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
57	Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology, 2003, 60, 1766-1769.	1.5	120
58	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117
59	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
60	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 931-933.	3.9	116
61	Rapidly Progressive Neurodegenerative Dementias. Archives of Neurology, 2009, 66, 201-7.	4.9	114
62	Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathologica, 2009, 118, 349-358.	3.9	114
63	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
64	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. Archives of Neurology, 2011, 68, 753-60.	4.9	110
65	Neurophysiologic Studies in Morvan Syndrome. Journal of Clinical Neurophysiology, 2004, 21, 440-445.	0.9	107
66	Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology, 2003, 61, 1134-1135.	1.5	106
67	Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. European Journal of Neurology, 2015, 22, 745-752.	1.7	106
68	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	0.8	106
69	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	2.2	105
70	The anatomic correlate of prosopagnosia in semantic dementia. Neurology, 2008, 71, 1628-1633.	1.5	104
71	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
72	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98

#	Article	IF	Citations
73	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
74	TAR DNAâ€binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Annals of Neurology, 2015, 78, 697-709.	2.8	96
75	Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain, 2008, 131, 460-472.	3.7	94
76	Fluorodeoxyglucose F18 Positron Emission Tomography in Progressive Apraxia of Speech and Primary Progressive Aphasia Variants. Archives of Neurology, 2010, 67, 596-605.	4.9	93
77	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
78	¹⁸F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2017, 58, 632-638.	2.8	91
79	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
80	Capgras Syndrome and Its Relationship to Neurodegenerative Disease. Archives of Neurology, 2007, 64, 1762.	4.9	89
81	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
82	Caudate atrophy on MRI is a characteristic feature of FTLDâ€FUS. European Journal of Neurology, 2010, 17, 969-975.	1.7	86
83	The neuroanatomy of pure apraxia of speech in stroke. Brain and Language, 2014, 129, 43-46.	0.8	83
84	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiology of Aging, 2015, 36, 1245-1252.	1.5	83
85	TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology, 2012, 79, 717-718.	1.5	81
86	High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970. Mayo Clinic Proceedings, 2017, 92, 66-71.	1.4	81
87	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
88	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
89	Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia. Journal of the International Neuropsychological Society, 2015, 21, 429-435.	1.2	78
90	Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology, 2005, 65, 645-647.	1.5	76

#	Article	IF	Citations
91	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
92	The alien limb phenomenon. Journal of Neurology, 2013, 260, 1880-1888.	1.8	75
93	Motor speech disorders associated with primary progressive aphasia. Aphasiology, 2014, 28, 1004-1017.	1.4	74
94	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
95	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
96	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
97	Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?. Neurology, 2010, 75, 2212-2220.	1.5	72
98	Adult onset Niemann-Pick disease type C presenting with psychosis. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 528-529.	0.9	71
99	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
100	Visual Hallucinations in Posterior Cortical Atrophy. Archives of Neurology, 2006, 63, 1427.	4.9	70
101	Argyrophilic grains: A distinct disease or an additive pathology?. Neurobiology of Aging, 2008, 29, 566-573.	1.5	70
102	Progranulin-associated PiB-negative logopenic primary progressive aphasia. Journal of Neurology, 2014, 261, 604-614.	1.8	69
103	Primary Progressive Apraxia of Speech: Clinical Features and Acoustic and Neurologic Correlates. American Journal of Speech-Language Pathology, 2015, 24, 88-100.	0.9	69
104	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
105	Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration. Archives of Neurology, 2004, 61, 1881-4.	4.9	67
106	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
107	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
108	Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease. Archives of Neurology, 2006, 63, 506.	4.9	66

#	Article	IF	Citations
109	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. Brain and Language, 2013, 125, 245-252.	0.8	66
110	The corticobasal syndromeâ€“Alzheimerâ€™s disease conundrum. Expert Review of Neurotherapeutics, 2011, 11, 1569-1578.	1.4	65
111	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
112	A Clinicopathological Study of Vascular Progressive Supranuclear Palsy. Archives of Neurology, 2002, 59, 1597.	4.9	64
113	Apolipoprotein E Îµ4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration. Archives of Neurology, 2004, 61, 1579.	4.9	64
114	Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase, 2012, 18, 478-488.	0.2	63
115	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. Neurology, 2014, 82, 1729-1735.	1.5	63
116	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
117	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. Journal of Molecular Neuroscience, 2011, 45, 372-8.	1.1	61
118	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. Journal of Neurology, 2014, 261, 710-716.	1.8	60
119	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSPâ€C. Movement Disorders, 2016, 31, 653-662.	2.2	60
120	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
121	Alien Hand Syndrome. Current Neurology and Neuroscience Reports, 2016, 16, 73.	2.0	59
122	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
123	Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. Brain and Language, 2017, 168, 84-94.	0.8	56
124	Progressive supranuclear palsy: progression and survival. Journal of Neurology, 2016, 263, 380-389.	1.8	55
125	Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. European Journal of Neurology, 2013, 20, 1417-1422.	1.7	54
126	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54

#	Article	IF	Citations
127	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimerâ€™s disease presenting as logopenic progressive aphasia. Brain and Language, 2013, 127, 127-134.	0.8	53
128	Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. Journal of Neurology, 2015, 262, 1483-1492.	1.8	53
129	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	1.9	53
130	Frontotemporal Lobar Degeneration Without Lobar Atrophy. Archives of Neurology, 2006, 63, 1632.	4.9	52
131	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	1.5	51
132	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
133	Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathologica, 2008, 116, 159-167.	3.9	50
134	Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. Mayo Clinic Proceedings, 2017, 92, 1291-1303.	1.4	50
135	Identification of an atypical variant of logopenic progressive aphasia. Brain and Language, 2013, 127, 139-144.	0.8	49
136	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	1.1	49
137	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	0.8	49
138	Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration. Neurobiology of Aging, 2007, 28, 1718-1722.	1.5	47
139	Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy. European Journal of Neurology, 2013, 20, 629-637.	1.7	47
140	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders, 2017, 32, 246-255.	2.2	46
141	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	2.2	46
142	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	1.4	46
143	Heterozygous Niemann-Pick disease type C presenting with tremor. Neurology, 2004, 63, 2189-2190.	1.5	45
144	Predicting functional decline in behavioural variant frontotemporal dementia. Brain, 2011, 134, 432-448.	3.7	45

#	Article	IF	Citations
145	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	1.2	45
146	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
147	Primary progressive apraxia of speech: from recognition to diagnosis and care. Aphasiology, 2021, 35, 560-591.	1.4	45
148	Hippocampal Sclerosis and Ubiquitin-Positive Inclusions in Dementia Lacking Distinctive Histopathology. Dementia and Geriatric Cognitive Disorders, 2004, 17, 342-345.	0.7	44
149	LATE to the PART-y. Brain, 2019, 142, e47-e47.	3.7	44
150	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	1.6	44
151	Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy. European Journal of Neurology, 2004, 11, 343-346.	1.7	43
152	Gray matter correlates of behavioral severity in progressive supranuclear palsy. Movement Disorders, 2011, 26, 493-498.	2.2	43
153	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	1.1	42
154	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317.	3.7	42
155	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. Neurobiology of Aging, 2008, 29, 1859-1863.	1.5	40
156	Minds on replay: musical hallucinations and their relationship to neurological disease. Brain, 2015, 138, 3793-3802.	3.7	40
157	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
158	Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology, 2004, 24, 149-152.	0.7	39
159	Recent Advances in the Imaging of Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 2012, 12, 715-723.	2.0	39
160	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	1.7	38
161	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain, 2013, 136, 455-470.	3.7	37
162	Diffuse Lewy body disease manifesting as corticobasal syndrome. Neurology, 2018, 91, e268-e279.	1.5	37

#	Article	IF	Citations
163	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
164	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
165	Modeling trajectories of regional volume loss in progressive supranuclear palsy. Movement Disorders, 2013, 28, 1117-1124.	2.2	36
166	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	1.4	36
167	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2018, 27, 1303-1318.	0.9	36
168	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.4	36
169	Frontotemporal Lobar Degeneration. Neurologic Clinics, 2007, 25, 683-696.	0.8	35
170	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.4	34
171	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	5.8	34
172	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
173	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
174	The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism and Related Disorders, 2014, 20, 180-185.	1.1	32
175	A Neuropsychiatric Analysis of the Cotard Delusion. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 58-65.	0.9	32
176	Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
177	Primary Progressive Aphasia and Apraxia of Speech. Seminars in Neurology, 2013, 33, 342-347.	0.5	31
178	APOE Îµ4 influences Î²â€amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimer's and Dementia, 2014, 10, 630-636.	0.4	31
179	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Annals of Neurology, 2006, 59, 200-203.	2.8	30
180	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. Neurology, 2017, 89, 2271-2279.	1.5	30

#	Article	IF	Citations
181	[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. Journal of Neurology, 2018, 265, 1079-1088.	1.8	29
182	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	0.8	29
183	Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathologica, 2005, 109, 427-432.	3.9	28
184	Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy. International Review of Psychiatry, 2013, 25, 197-209.	1.4	28
185	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
186	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	1.1	27
187	Corticobasal degeneration: key emerging issues. Journal of Neurology, 2018, 265, 439-445.	1.8	27
188	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
189	Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology, 2002, 59, 645-645.	1.5	26
190	Ifosfamide associated myoclonus-encephalopathy syndrome. Journal of Neurology, 2011, 258, 1729-1731.	1.8	26
191	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. Journal of Alzheimer's Disease, 2018, 66, 1015-1025.	1.2	26
192	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	0.8	26
193	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
194	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.2	25
195	Dysphagia in Progressive Supranuclear Palsy. Dysphagia, 2020, 35, 667-676.	1.0	25
196	FRONTOTEMPORAL LOBAR DEGENERATION WITH UPPER MOTOR NEURON DISEASE/ PRIMARY LATERAL SCLEROSIS. Neurology, 2007, 69, 1800-1801.	1.5	24
197	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029.	1.2	24
198	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24

#	Article	IF	Citations
199	Western Aphasia Batteryâ€“Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2020, 29, 498-510.	0.9	24
200	The clinical spectrum of stereotypies in frontotemporal lobar degeneration. Movement Disorders, 2009, 24, 1237-1240.	2.2	22
201	TDP-43 in Alzheimerâ€™s disease is not associated with clinical FTLD or Parkinsonism. Journal of Neurology, 2014, 261, 1344-1348.	1.8	22
202	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	1.1	22
203	MRI correlates of alien leg-like phenomenon in corticobasal degeneration. Movement Disorders, 2005, 20, 870-873.	2.2	21
204	The relationship between histopathological features of progressive supranuclear palsy and disease duration. Parkinsonism and Related Disorders, 2006, 12, 109-112.	1.1	21
205	Ideomotor apraxia in agrammatic and logopenic variants of primary progressive aphasia. Journal of Neurology, 2013, 260, 1594-1600.	1.8	21
206	Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology, 2015, 262, 783-788.	1.8	21
207	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
208	The clinical spectrum and natural history of pure akinesia with gait freezing. Journal of Neurology, 2016, 263, 2419-2423.	1.8	21
209	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
210	Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid. European Journal of Neurology, 2012, 19, 1440-1446.	1.7	20
211	TDP-43 and Alzheimerâ€™s Disease Pathologic Subtype in Non-Amnestic Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2018, 64, 1227-1233.	1.2	20
212	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. Parkinsonism and Related Disorders, 2020, 81, 34-40.	1.1	20
213	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19
214	Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 107-111.	1.1	19
215	Clinicopathologic discrepancies in a populationâ€based incidence study of parkinsonism in olmsted county: 1991â€2010. Movement Disorders, 2017, 32, 1439-1446.	2.2	19
216	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19

#	Article	IF	Citations
217	Quantitative Analysis of Agrammatism in Agrammatic Primary Progressive Aphasia and Dominant Apraxia of Speech. Journal of Speech, Language, and Hearing Research, 2018, 61, 2337-2346.	0.7	19
218	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	1.1	19
219	The Alien Limb. Practical Neurology, 2004, 4, 44-45.	0.5	18
220	Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease. Movement Disorders, 2005, 20, 1515-1520.	2.2	18
221	Coprophagia in neurologic disorders. Journal of Neurology, 2016, 263, 1008-1014.	1.8	18
222	The diagnosis of progressive supranuclear palsy: current opinions and challenges. Expert Review of Neurotherapeutics, 2018, 18, 603-616.	1.4	18
223	Regional Î²â€amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. European Journal of Neurology, 2016, 23, 313-319.	1.7	17
224	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. Frontiers in Neurology, 2019, 10, 939.	1.1	17
225	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
226	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
227	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
228	Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology, 2019, 93, e1339-e1347.	1.5	16
229	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. Brain and Language, 2020, 204, 104773.	0.8	15
230	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
231	Submentalis Rapid Eye Movement Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy. Annals of Neurology, 2019, 86, 969-974.	2.8	14
232	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1655-1662.	2.2	14
233	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14
234	Prominent auditory deficits in primary progressive aphasia: A case study. Cortex, 2019, 117, 396-406.	1.1	14

#	Article	IF	Citations
235	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 78, 927-937.	1.2	14
236	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
237	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
238	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. Movement Disorders, 2022, 37, 702-712.	2.2	14
239	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14
240	Phonologic errors in the logopenic variant of primary progressive aphasia. Aphasiology, 2014, 28, 1223-1243.	1.4	13
241	Rest in peace FTDP-17. Brain, 2018, 141, 324-331.	3.7	13
242	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
243	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. American Journal of Speech-Language Pathology, 2020, 29, 1976-1986.	0.9	13
244	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
245	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	1.4	13
246	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
247	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. European Journal of Neurology, 2018, 25, 1352-1357.	1.7	12
248	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. Journal of Neurology, 2020, 267, 2603-2611.	1.8	12
249	Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt <scp>Alphaâ€Synucleinopathies</scp>. Annals of Neurology, 2021, 89, 293-303.	2.8	12
250	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	1.8	12
251	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. American Journal of Speech-Language Pathology, 2021, 30, 1361-1372.	0.9	12
252	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12

#	Article	IF	Citations
253	Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. Movement Disorders, 2012, 27, 903-906.	2.2	11
254	Unlocking the mysteries of TDP-43. Neurology, 2015, 84, 870-871.	1.5	11
255	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. Neurocase, 2016, 22, 55-59.	0.2	11
256	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
257	C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathologica Communications, 2019, 7, 100.	2.4	11
258	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.4	11
259	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11
260	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	1.4	11
261	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	1.8	10
262	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. NeuroImage: Clinical, 2016, 11, 90-98.	1.4	10
263	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
264	Progressive Supranuclear Palsy and Corticobasal Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 151-176.	0.8	10
265	Old age genetically confirmed frontotemporal lobar degeneration with TDPâ€43 has limbic predominant TDPâ€43 deposition. Neuropathology and Applied Neurobiology, 2021, 47, 1050-1059.	1.8	10
266	Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia. European Journal of Neurology, 2014, 21, 1040-1043.	1.7	9
267	TDPâ€43 in the olfactory bulb in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2016, 42, 390-393.	1.8	9
268	Electroencephalography in primary progressive aphasia and apraxia of speech. Aphasiology, 2019, 33, 1410-1417.	1.4	9
269	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.5	9
270	Natural History of â€œPureâ€•Primary Lateral Sclerosis. Neurology, 2021, 96, e2231-e2238.	1.5	9

#	Article	IF	Citations
271	Relationship Between ¹⁸F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies. Journal of Nuclear Medicine, 2022, 63, 931-935.	2.8	9
272	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Neurology: Clinical Practice, 2021, 11, 249-255.	0.8	9
273	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 78, 200-203.	1.1	8
274	Cerebrovascular pathology and misdiagnosis of multiple system atrophy: An autopsy study. Parkinsonism and Related Disorders, 2020, 75, 34-40.	1.1	8
275	Phonological Errors in Posterior Cortical Atrophy. Dementia and Geriatric Cognitive Disorders, 2021, 50, 195-203.	0.7	8
276	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2022, 9, 212-217.	0.8	8
277	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. NeuroImage: Clinical, 2022, 35, 103030.	1.4	8
278	Occupational Differences Between Alzheimerâ€™s and Aphasic Dementias. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 612-616.	0.9	7
279	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
280	Quantitative assessment of grammar in amyloid-negative logopenic aphasia. Brain and Language, 2018, 186, 26-31.	0.8	7
281	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
282	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. Journal of Speech, Language, and Hearing Research, 2021, 64, 392-404.	0.7	7
283	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7
284	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. Neurology, 2021, 97, 908-909.	1.5	7
285	Posterior cortical atrophy: Primary occipital variant. European Journal of Neurology, 2022, 29, 2138-2143.	1.7	7
286	APOE Îµ4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 784-796.	0.4	7
287	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263.	0.2	6
288	Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imagingâ€pathology study. European Journal of Neurology, 2021, 28, 670-675.	1.7	6

#	Article	IF	Citations
289	Autopsy Validation of Progressive Supranuclear Palsyâ€Predominant Speech/Language Disorder Criteria. Movement Disorders, 2022, 37, 213-218.	2.2	6
290	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
291	Old age amyotrophic lateral sclerosis and limbic TDPâ€43 pathology. Brain Pathology, 2022, 32, .	2.1	6
292	Dementia and the TAR DNA Binding Protein 43. Clinical Pharmacology and Therapeutics, 2010, 88, 555-558.	2.3	5
293	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. Journal of the Acoustical Society of America, 2018, 144, 3364-3370.	0.5	5
294	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	1.1	5
295	PSP-like syndrome after aortic surgery in adults (Mokri syndrome). Neurology: Clinical Practice, 2020, 10, 245-254.	0.8	5
296	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 17-28.	0.7	5
297	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. Journal of Neurology, 2021, 268, 4752-4758.	1.8	5
298	Neurodegeneration of the visual word form area in a patient with word form alexia. Neurology and Clinical Neuroscience, 2021, 9, 359-360.	0.2	5
299	Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100Âyears. Journal of Neurology, 2022, 269, 4030-4054.	1.8	5
300	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	1.5	5
301	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
302	Rare Tauopathies. Seminars in Neurology, 2019, 39, 264-273.	0.5	4
303	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
304	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. Neurocase, 2021, 27, 212-222.	0.2	4
305	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	2.2	4
306	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 91, 9-12.	1.1	4

#	Article	IF	Citations
307	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
308	Word Fluency Test Performance in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2021, 30, 2635-2642.	0.9	4
309	Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia. Neuropathology, 2022, 42, 82-89.	0.7	4
310	Clinical Aspects of TDPâ€43 Proteinopathy, Neurofilament Inclusion Body Disease and Dementias Lacking Distinctive Proteinopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 377-382.	1.0	3
311	Fitting TDP-43 into the APOE Îµ4 and neurodegeneration story. Lancet Neurology, The, 2018, 17, 735-737.	4.9	3
312	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	1.5	3
313	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
314	Pramipexole induced compulsive behaviors abate after initiation of rotigitine. Movement Disorders, 2009, 24, 1090-1091.	2.2	2
315	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	1.5	2
316	Molecular neuroimaging in primary progressive aphasia with predominant agraphia. Neurocase, 2018, 24, 121-123.	0.2	2
317	Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 554-561.	1.1	2
318	Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. Parkinsonism and Related Disorders, 2022, 101, 9-14.	1.1	2
319	TDP-43 AMPLIFIES MEMORY LOSS AND HIPPOCAMPAL ATROPHY IN ALZHEIMER'S DISEASE. , 2014, 10, P279-P280.		1
320	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. Journal of the International Neuropsychological Society, 2022, 28, 441-451.	1.2	1
321	Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech and Aphasia: A 1-Year Follow-Up Study. American Journal of Speech-Language Pathology, 2021, 30, 1-11.	0.9	1
322	Review: Transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathology and Applied Neurobiology, 2010, 36, 97-112.	1.8	1
323	A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia. Brain Sciences, 2022, 12, 378.	1.1	1
324	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Dementia and Geriatric Cognitive Disorders, 2022, 51, 193-202.	0.7	1

#	Article	IF	Citations
325	Mild cognitive impairment. , 2005, , 409-415.		0
326	Imaging brain atrophy in progressive supranuclear palsy and corticobasal syndromes: potential for diagnosis and monitoring of disease progression. Neurodegenerative Disease Management, 2012, 2, 589-598.	1.2	0
327	Frontotemporal dementia: a peek under its invisibility cloak. Lancet Neurology, The, 2015, 14, 236-237.	4.9	0
328	P1â€270: AVâ€1451 TAUâ€PET in Clinical Variants of Progressive Supranuclear Palsy. Alzheimer's and Dementia, 2016, 12, P518.	0.4	0
329	ICâ€Pâ€188: AVâ€1451 TAUâ€PET In Clinical Variants of Progressive Supranuclear Palsy. Alzheimer's and Dementia, 2016, 12, P136.	0.4	0
330	[P4â€“531]: TDPâ€43 DRIVES FASTER RATES OF HIPPOCAMPAL ATROPHY IN ALZHEIMER's DISEASE STARTING AT LEAST 10 YEARS PRIOR TO DEATH. Alzheimer's and Dementia, 2017, 13, P1553.	0.4	0
331	Curious case of FTD-ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1255-1255.	0.9	0
332	A Cognitive Psychometric Investigation of Word Production and Phonological Error Rates in Logopenic Progressive Aphasia. American Journal of Speech-Language Pathology, 2021, 30, 1194-1202.	0.9	0
333	Tau Negative FTLD Without Abnormal TDPâ€43 Immunoreactivity. FASEB Journal, 2008, 22, 707.13.	0.2	0
334	Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0